Shauna Applin
Community Health · Tacoma, WANPI 1922167261
Payments from drug & device makers
Across 374 payments — averaging $504.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$180K
- Merck$4K
- Janssen Products, LP$3K
- Viiv Healthcare Company$2K
What the payments were for
- Consulting fees$22,64214%
- Speaking & faculty fees$85,79154%
- Travel & lodging$42,01327%
- Food & beverage$8,0425%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 357 | $180,021 |
| Merck | 4 | $3,565 |
| Janssen Products, LP | 11 | $2,902 |
| Viiv Healthcare Company | 2 | $2,117 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few community health providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 540 | $2,154,580 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 44 | $179,839 |
| TivicayDolutegravir Sodium | 58 | $160,212 |
| DescovyEmtricitabine/Tenofov Alafenam | 41 | $90,140 |
| JulucaDolutegravir/Rilpivirine | 17 | $58,957 |
| PrezcobixDarunavir/Cobicistat | 23 | $54,296 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $44,594 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $39,626 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $38,167 |
| IsentressRaltegravir Potassium | 17 | $34,709 |
| Maraviroc | 22 | $22,791 |
| JardianceEmpagliflozin | 29 | $17,159 |
| XareltoRivaroxaban | 29 | $16,517 |
| Darunavir | 12 | $13,871 |
| Etravirine | 11 | $11,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $180,021 | $2,424,559625 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Triumeq | $2,117 | $303,38897 claims |
| MerckIsentress | $3,565 | $34,70917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few community health providers in Washingtonon file to place this against a meaningful peer group, so we don't.
Other community health in Tacoma
- Naomi WardDeer Park$481
- Donna HenryDeer Park$444
- Sonia ReidSpokane Valley$359
- Wendy WhitePort Townsend$24
- Audrey SwannBellingham$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.